Benchmark Downgrades Insulet Corporation (PODD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Raises Price Target on Insulet (PODD) Following 2Q15 Results
August 13, 2015 10:16 AM EDTLeerink Partners reiterated an Outperform rating on Insulet Corporation (NASDAQ: PODD), and raised the price target to $44.00 (from $40.00), following the company's 2Q15 earnings report. PODD reported 2Q15 sales of $75.6M, in line with the July 29th preannouncement, and coming in ~$4M ahead of the Street.
Analyst Danielle Antalffy commented, "Last night, PODD reported 2Q15 sales of $75.6M (+5%y/ y) -- in line with the July 29th... More
Piper Jaffray Raises Price Target on Insulet (PODD) to $41 Following 2Q Earnings
August 13, 2015 8:30 AM EDTPiper Jaffray reiterated an Overweight rating on Insulet Corporation (NASDAQ: PODD), and raised the price target to $41.00 (from $36.00), following the company's 2Q earnings report. PODD reported 2Q revenues of $75.6M, in-line with preannounced results, and above consensus of $68.9M and company guidance of $67M-$70M. Management reaffirmed full year revenue guidance... More
Insulet (PODD) Misses Q2 EPS by 14c, Sales Beat
August 12, 2015 4:03 PM EDTInsulet (NASDAQ: PODD) reported Q2 EPS of ($0.27), $0.14 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $75.6 million versus the consensus estimate of $70.75 million.
Insulet sees FY2015 revenue of $300-320 million, versus the consensus of $304.4 million.
"We are very... More
